SKYE
Skye Bioscience, Inc.
1.70$
-1.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 89.4% | 72.8% | 88.5% | 98.4% | 86.4% | 99.7% | 99.8% | 99.9% | 99.7% | 97.5% | 98.2% | 97.6% | 97.3% | 95.7% | |
| 61.6% | 35.8% | 59.5% | 91.7% | 20.0% | 46.7% | 94.7% | 91.6% | 92.4% | 91.2% | 13.7% | 10.5% | 94.0% | 20.8% | |
| 61.6% | 35.8% | 59.5% | 91.7% | 20.0% | 46.7% | 94.7% | 91.6% | 92.4% | 91.2% | 13.7% | 10.5% | 94.0% | 90.9% | |
| 27.9% | 17.4% | – | – | – | – | – | – | – | – | 0.8% | 1.3% | 0.0% | 0.0% | |
| – | 8.9% | – | – | – | – | – | – | – | – | 79.2% | 1.1% | – | – | |
| – | – | – | – | 3.0% | 0.3% | 0.2% | 0.1% | 0.3% | 2.4% | – | – | – | – | |
| 10.1% | 125.0% | 230.2% | 86.6% | 548.7% | 243.6% | 895.2% | 72.6% | 83.1% | 40.5% | 133.0% | 117.9% | 6.3% | 29.3% | |
| 10.1% | 125.0% | 230.0% | 16.6% | 204.7% | 144.6% | 814.4% | 48.6% | 29.5% | 39.7% | 133.0% | 116.4% | 6.0% | 29.0% | |
| – | – | – | – | – | 42.2% | – | – | 2.4% | 20.9% | 21.2% | 37.2% | 0.3% | 0.7% | |
| 9.5% | 1.5% | 117.6% | 3.6% | 84.9% | 18.1% | 0.8% | 7.0% | 14.3% | 9.1% | 19.7% | 8.0% | 0.8% | 7.2% | |
| – | – | – | – | – | – | 69.5% | 19.4% | 53.7% | – | – | – | – | – | |
| 89.9% | -125.0% | -130.2% | 13.4% | -448.7% | -143.6% | -795.2% | 27.4% | 16.9% | 59.5% | -33.0% | -17.9% | 93.7% | 70.7% | |
| 1.1% | -125.7% | -837.5% | -221.0% | -3,382.1% | -2,518.0% | -1,697.6% | -1,611.3% | -1,449.8% | -479.5% | -732.5% | -874.2% | -180.0% | -660.0% | |
| 10.0% | 2.9% | 1.5% | 0.2% | 3.1% | 2.7% | 3.4% | 3.3% | 4.3% | 2.1% | 5,418.2% | 7.3% | 6.3% | 17.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.